{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:15:39Z","timestamp":1781478939164,"version":"3.54.1"},"reference-count":173,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20232ACB206042"],"award-info":[{"award-number":["20232ACB206042"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060577"],"award-info":[{"award-number":["82060577"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260628"],"award-info":[{"award-number":["82260628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360629"],"award-info":[{"award-number":["82360629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bbcan.2023.189008","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T23:39:29Z","timestamp":1698795569000},"page":"189008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy"],"prefix":"10.1016","volume":"1878","author":[{"given":"Yuxi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.bbcan.2023.189008_bb0005","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189008_bb0010","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.bbcan.2023.189008_bb0015","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189008_bb0020","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189008_bb0025","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189008_bb0030","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"issue":"29","key":"10.1016\/j.bbcan.2023.189008_bb0035","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.bbcan.2023.189008_bb0040","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189008_bb0045","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10124","key":"10.1016\/j.bbcan.2023.189008_bb0050","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189008_bb0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jaccao.2021.06.007","article-title":"Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification","volume":"3","author":"Bergom","year":"2021","journal-title":"JACC CardioOncol."},{"issue":"13","key":"10.1016\/j.bbcan.2023.189008_bb0060","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2016.71.6142","article-title":"Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer","volume":"35","author":"Dess","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.bbcan.2023.189008_bb0065","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2016.70.0229","article-title":"Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy","volume":"35","author":"Wang","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189008_bb0070","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189008_bb0075","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189008_bb0080","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1078-0432.CCR-17-3269","article-title":"Beyond concurrent chemoradiation: the emerging role of PD-1\/PD-L1 inhibitors in stage III lung cancer","volume":"24","author":"McCall","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"20","key":"10.1016\/j.bbcan.2023.189008_bb0090","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2023.189008_bb0095","article-title":"Toxicity profile of combining PD-1\/PD-L1 inhibitors and thoracic radiotherapy in non-small cell lung cancer: a systematic review","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189008_bb0100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the international cardio-oncology society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-022-01041-4","article-title":"New insights into the understanding of mechanisms of radiation-induced heart disease","volume":"24","author":"Wang","year":"2023","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"41","key":"10.1016\/j.bbcan.2023.189008_bb0110","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0115","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jtho.2017.12.002","article-title":"PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes","volume":"13","author":"Du","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2023.189008_bb0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ctrv.2018.04.001","article-title":"Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer","volume":"66","author":"Skrzypski","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189008_bb0125","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","article-title":"Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches","volume":"33","author":"Cortiula","year":"2022","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2023.189008_bb0135","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/cncr.33083","article-title":"A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179","volume":"126","author":"Durm","year":"2020","journal-title":"Cancer"},{"issue":"29","key":"10.1016\/j.bbcan.2023.189008_bb0140","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2023.189008_bb0145","series-title":"Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III Non-Small Cell Lung Cancer: BTCRC LUN 16-081","first-page":"8509","volume":"40(16_suppl)","author":"Durm","year":"2022"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189008_bb0155","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2023.189008_bb0160","series-title":"AFT-16: Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab and Chemoradiation (CRT) for Stage III Non-Small Cell Lung Cancer (NSCLC)","first-page":"8513","volume":"39(15_suppl)","author":"Ross","year":"2021"},{"issue":"9","key":"10.1016\/j.bbcan.2023.189008_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jtho.2019.10.024","article-title":"Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC","volume":"15","author":"Lin","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0175","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"Peters","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189008_bb0180","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/j.cllc.2022.04.003","article-title":"Rationale and design of the phase III KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for stage III non-small-cell lung cancer","volume":"23","author":"Jabbour","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189008_bb0185","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","volume":"23","author":"De Ruysscher","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bbcan.2023.189008_bb0190","first-page":"33","article-title":"965P real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: a multi-Centre, Australian experience","author":"Stevens","year":"2022","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189008_bb0195","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.jtho.2017.04.029","article-title":"Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD-L1-negative metastatic squamous cell carcinoma of the lung","volume":"12","author":"Yuan","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189008_bb0200","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.21037\/tlcr-21-682","article-title":"Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer","volume":"10","author":"Wang","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0205","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbcan.2019.02.004","article-title":"Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1\/PD-L1 therapy with thoracic radiotherapy","volume":"1871","author":"Li","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"17","key":"10.1016\/j.bbcan.2023.189008_bb0210","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.bbcan.2023.189008_bb0215","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.bbcan.2023.189008_bb0220","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189008_bb0225","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2023.189008_bb0230","article-title":"Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2023.189008_bb0235","series-title":"Analysis of Patterns of Care and Benefit of Thoracic Radiotherapy for Patients with Stage IV NSCLC in the Immunotherapy-Era from a National Hospital-Based Registry","first-page":"9123","volume":"39(15_suppl)","author":"Kharouta","year":"2021"},{"issue":"5","key":"10.1016\/j.bbcan.2023.189008_bb0240","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0245","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2023.189008_bb0250","doi-asserted-by":"crossref","first-page":"1025455","DOI":"10.3389\/fonc.2022.1025455","article-title":"Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy","volume":"12","author":"Son","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2023.189008_bb0255","article-title":"Cardiovascular adverse events induced by immune checkpoint inhibitors: a real world study from 2018 to 2022","volume":"9","author":"Wu","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189008_bb0260","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0265","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21037\/atm-21-6256","article-title":"Comparison of stereotactic body radiotherapy and radiofrequency ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"16","key":"10.1016\/j.bbcan.2023.189008_bb0275","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/cncr.30693","article-title":"7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: results of a phase 2 clinical trial","volume":"123","author":"Sun","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2023.189008_bb0280","series-title":"Adjuvant Vinorelbine Plus Cisplatin Versus Observation in Patients with Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A Randomised Controlled Trial","first-page":"719","volume":"7(9)","author":"Douillard","year":"2006"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0285","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1200\/JCO.2009.24.0333","article-title":"Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage, IB and II Non\u2013Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10","volume":"28","author":"Butts","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2023.189008_bb0290","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1200\/JCO.2020.38.15_suppl.9011","article-title":"Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer","volume":"38","author":"Kelly","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2023.189008_bb0295","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1200\/JCO.2020.38.15_suppl.9035","article-title":"I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: interim analysis adverse effects","volume":"38","author":"Chang","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189008_bb0300","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0305","doi-asserted-by":"crossref","first-page":"S729","DOI":"10.1016\/S1556-0864(21)01905-5","article-title":"63MO safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: a first report of a randomized phase II trial (ASTEROID)","volume":"16","author":"Hallqvist","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"10405","key":"10.1016\/j.bbcan.2023.189008_bb0310","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189008_bb0315","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.radonc.2016.04.025","article-title":"Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation","volume":"119","author":"Tucker","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189008_bb0320","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0325","article-title":"The diagnosis and management of immune checkpoint inhibitor cardiovascular toxicity: myocarditis and beyond","volume":"10","author":"Gilon","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189008_bb0330","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2023.189008_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","article-title":"Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials","volume":"107","author":"Kanjanapan","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2023.189008_bb0340","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189008_bb0345","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"10","key":"10.1016\/j.bbcan.2023.189008_bb0350","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000261","article-title":"Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"8","author":"Dolladille","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0360","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","article-title":"Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms","volume":"33","author":"Champion","year":"2020","journal-title":"Mod. Pathol."},{"issue":"15","key":"10.1016\/j.bbcan.2023.189008_bb0365","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"5502","key":"10.1016\/j.bbcan.2023.189008_bb0370","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"issue":"5238","key":"10.1016\/j.bbcan.2023.189008_bb0375","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0380","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189008_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031426","article-title":"Programmed death-ligand 2 deficiency exacerbates experimental autoimmune myocarditis in mice","volume":"22","author":"Li","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189008_bb0390","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189008_bb0395","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxq026","article-title":"PD-1 deficiency results in the development of fatal myocarditis in MRL mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int. Immunol."},{"issue":"24","key":"10.1016\/j.bbcan.2023.189008_bb0400","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1002\/cam4.4814","article-title":"Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1\/PD-L1 pathway in multiple myeloma","volume":"11","author":"Zhang","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2023.189008_bb0405","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fimmu.2020.01276","article-title":"Antigen cross-presentation by macrophages","volume":"11","author":"Muntjewerff","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0410","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1373231","article-title":"Toll-like receptor 2 ligand and interferon-\u03b3 suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells","volume":"7","author":"Shime","year":"2017","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.bbcan.2023.189008_bb0415","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41419-020-02778-2","article-title":"Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a\/Kruppel-like factor 4 signaling","volume":"11","author":"Xia","year":"2020","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0420","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.etap.2015.02.019","article-title":"The inflammasome accelerates radiation-induced lung inflammation and fibrosis in mice","volume":"39","author":"Sohn","year":"2015","journal-title":"Environ. Toxicol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0425","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2326-6066.CIR-21-0839","article-title":"Autoantibodies drive heart damage caused by concomitant radiation and PD-1 blockade","volume":"11","author":"Yan","year":"2023","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0430","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2006.08.071","article-title":"Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?","volume":"67","author":"Schultz-Hector","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.bbcan.2023.189008_bb0435","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.clon.2013.06.012","article-title":"Understanding radiation-induced cardiovascular damage and strategies for intervention","volume":"25","author":"Stewart","year":"2013","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0440","first-page":"54","article-title":"Histopathological efficiency of amifostine in radiation-induced heart disease in rats","volume":"119","author":"Gurses","year":"2018","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.bbcan.2023.189008_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117342","article-title":"BRCA1 protects cardiac microvascular endothelial cells against irradiation by regulating p21-mediated cell cycle arrest","volume":"244","author":"Zeng","year":"2020","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189008_bb0450","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/00007890-200106270-00007","article-title":"Mast cells in acute and chronic rejection of rat cardiac allografts\u2013a major source of basic fibroblast growth factor","volume":"71","author":"Koskinen","year":"2001","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.bbcan.2023.189008_bb0455","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/acel.12253","article-title":"Premature aging induced by radiation exhibits pro-atherosclerotic effects mediated by epigenetic activation of CD44 expression","volume":"13","author":"Lowe","year":"2014","journal-title":"Aging Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0460","doi-asserted-by":"crossref","first-page":"H392","DOI":"10.1152\/ajpheart.00124.2017","article-title":"Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction","volume":"313","author":"Saiki","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0465","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2010.09.002","article-title":"Pathogenetic mechanisms in radiation fibrosis","volume":"97","author":"Yarnold","year":"2010","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0470","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2012.04.033","article-title":"Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint","volume":"53","author":"Yamamori","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189008_bb0475","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2796.2011.02353.x","article-title":"Cardiovascular disease associated with radiotherapy: activation of nuclear factor kappa-B","volume":"269","author":"Halle","year":"2011","journal-title":"J. Intern. Med."},{"issue":"13","key":"10.1016\/j.bbcan.2023.189008_bb0480","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1089\/ars.2017.7064","article-title":"Role of platelet-derived transforming growth factor-\u03b21 and reactive oxygen species in radiation-induced organ fibrosis","volume":"27","author":"Ahamed","year":"2017","journal-title":"Antioxid. Redox Signal."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189008_bb0485","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2023.189008_bb0490","article-title":"Oncostatin M\/Oncostatin M receptor signal induces radiation-induced heart fibrosis by regulating SMAD4 in fibroblast","author":"Xu","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2023.189008_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108551","article-title":"PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model","volume":"105","author":"Chen","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189008_bb0500","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2169\/internalmedicine.5317-20","article-title":"The cytokine expression in patients with cardiac complication after immune checkpoint inhibitor therapy","volume":"60","author":"Tsuruda","year":"2021","journal-title":"Intern. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2023.189008_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102498","article-title":"Comparative transcriptomics of immune checkpoint inhibitor myocarditis identifies guanylate binding protein 5 and 6 dysregulation","volume":"13","author":"Finke","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2023.189008_bb0510","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/JIR.S348464","article-title":"Protective effect of crocin on immune checkpoint inhibitors-related myocarditis through inhibiting NLRP3 mediated pyroptosis in cardiomyocytes via NF-\u03baB pathway","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"17","key":"10.1016\/j.bbcan.2023.189008_bb0515","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1161\/01.CIR.0000093661.90582.c4","article-title":"Oxidative stress and cardiovascular injury: part II: animal and human studies","volume":"108","author":"Griendling","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189008_bb0520","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCRESAHA.114.300559","article-title":"Cardiac mitochondria and reactive oxygen species generation","volume":"114","author":"Chen","year":"2014","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189008_bb0525","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12482","article-title":"Radiation-induced dysfunction of energy metabolism in the heart results in the fibrosis of cardiac tissues","volume":"24","author":"Xu","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbcan.2023.189008_bb0530","doi-asserted-by":"crossref","first-page":"1112222","DOI":"10.3389\/fcvm.2023.1112222","article-title":"Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis","volume":"10","author":"Zhang","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0535","first-page":"R476","article-title":"Novel roles of immunometabolism and nonmyocyte metabolism in cardiac remodeling and injury","volume":"319","author":"Mouton","year":"2020","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"issue":"19","key":"10.1016\/j.bbcan.2023.189008_bb0540","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1111\/febs.15644","article-title":"Metabolic dysfunction and inflammatory disease: the role of stromal fibroblasts","volume":"288","author":"Farah","year":"2021","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0545","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.bbcan.2023.189008_bb0550","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","article-title":"Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials","volume":"35","author":"Taylor","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189008_bb0555","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.ijrobp.2021.03.005","article-title":"Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy","volume":"110","author":"Atkins","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2023.189008_bb0560","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijcard.2020.04.033","article-title":"Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice","volume":"313","author":"Tsuruoka","year":"2020","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0565","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0169-5002(98)00039-7","article-title":"Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study","volume":"21","author":"Janssen-Heijnen","year":"1998","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbcan.2023.189008_bb0570","series-title":"Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology","first-page":"1079","article-title":"Comorbidity and survival in lung cancer patients","volume":"24(7)","author":"Islam","year":"2015"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0575","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamaoncol.2020.6332","article-title":"Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer","volume":"7","author":"Atkins","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbcan.2023.189008_bb0580","series-title":"Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","first-page":"1220","article-title":"Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment","volume":"21(9)","author":"Herrero Rivera","year":"2019"},{"key":"10.1016\/j.bbcan.2023.189008_bb0585","article-title":"The distribution of cardiovascular-related comorbidities in different adult-onset cancers and related risk factors: analysis of 10 year retrospective data","volume":"8","author":"Li","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189008_bb0590","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189008_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113480","article-title":"Pre-existing cardiovascular conditions as clinical predictors of myocarditis reporting with immune checkpoint inhibitors: a VigiBase study","volume":"12","author":"Noseda","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.bbcan.2023.189008_bb0600","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1093\/oncolo\/oyac056","article-title":"Incidence, clinical characteristics, and predictors of cardiovascular immune-related adverse events associated with immune checkpoint inhibitors","volume":"27","author":"Isawa","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2023.189008_bb0605","article-title":"Myocardial PD-L1 expression in patients with ischemic and non-ischemic heart failure","volume":"8","author":"Kushnareva","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.bbcan.2023.189008_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.914928","article-title":"Intrinsic differences in immune checkpoint inhibitor-induced myocarditis: a retrospective analysis of real world data","volume":"13","author":"Lei","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0615","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12885-020-07741-0","article-title":"Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0620","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ijrobp.2005.10.022","article-title":"Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study","volume":"64","author":"Hooning","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"669","key":"10.1016\/j.bbcan.2023.189008_bb0625","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo1981","article-title":"Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis","volume":"14","author":"Zhang","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189008_bb0630","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaccao.2022.11.008","article-title":"Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy","volume":"4","author":"Lee","year":"2022","journal-title":"JACC CardioOncol."},{"issue":"28","key":"10.1016\/j.bbcan.2023.189008_bb0635","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2023.189008_bb0640","doi-asserted-by":"crossref","first-page":"1065510","DOI":"10.3389\/fimmu.2023.1065510","article-title":"Safety and efficacy of radiotherapy\/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: a systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.bbcan.2023.189008_bb0645","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","article-title":"Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC state-of-the-art review","volume":"77","author":"Rao","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189008_bb0650","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0655","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189008_bb0660","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.bbcan.2023.189008_bb0665","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189008_bb0670","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189008_bb0675","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189008_bb0680","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"21","key":"10.1016\/j.bbcan.2023.189008_bb0685","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0690","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ijrobp.2021.07.035","article-title":"Assessment of prognostic value of high-sensitivity cardiac troponin T for early prediction of chemoradiation therapy-induced cardiotoxicity in patients with non-small cell lung cancer: a secondary analysis of a prospective randomized trial","volume":"111","author":"Xu","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189008_bb0695","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa031994","article-title":"Plasma natriuretic peptide levels and the risk of cardiovascular events and death","volume":"350","author":"Wang","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0700","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004675","article-title":"The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis","volume":"4","author":"Taylor","year":"2014","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.bbcan.2023.189008_bb0705","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.2001.19.10.2746","article-title":"Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients","volume":"19","author":"Meinardi","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.bbcan.2023.189008_bb0710","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189008_bb0715","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","article-title":"Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient","volume":"11","author":"Plana","year":"2018","journal-title":"J. Am. Coll. Cardiol. Img."},{"issue":"15","key":"10.1016\/j.bbcan.2023.189008_bb0720","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.116.025434","article-title":"Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer","volume":"135","author":"Saiki","year":"2017","journal-title":"Circulation"},{"issue":"31","key":"10.1016\/j.bbcan.2023.189008_bb0725","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"Romond","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.bbcan.2023.189008_bb0730","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin adjuvant trial (BIG 1-01)","volume":"32","author":"de Azambuja","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2023.189008_bb0735","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189008_bb0740","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/heartjnl-2019-316297","article-title":"Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity","volume":"106","author":"Lambert","year":"2020","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0745","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189008_bb0750","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jcmg.2018.06.004","article-title":"Cardiovascular magnetic resonance in the oncology patient","volume":"11","author":"Jordan","year":"2018","journal-title":"J. Am. Coll. Cardiol. Img."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0755","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CRD.0b013e318197e950","article-title":"The utility of cardiovascular magnetic resonance in constrictive pericardial disease","volume":"17","author":"Ariyarajah","year":"2009","journal-title":"Cardiol. Rev."},{"issue":"20","key":"10.1016\/j.bbcan.2023.189008_bb0760","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJM200011163432003","article-title":"The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction","volume":"343","author":"Kim","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0765","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review","volume":"18","author":"Haaf","year":"2016","journal-title":"J. Cardiovasc. Magn. Reson.: Off. J. Soc. Cardiovasc. Magn. Reson."},{"issue":"18","key":"10.1016\/j.bbcan.2023.189008_bb0770","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0775","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"10.1016\/j.bbcan.2023.189008_bb0780","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamaoncol.2020.7468","article-title":"Association of breast cancer irradiation with cardiac toxic effects: a narrative review","volume":"7","author":"Meattini","year":"2021","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0785","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","article-title":"Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions","volume":"16","author":"Banfill","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0790","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13014-019-1234-z","article-title":"Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study)","volume":"14","author":"Jacob","year":"2019","journal-title":"Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189008_bb0795","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11912-023-01387-4","article-title":"Cardiovascular toxicity and risk mitigation with lung cancer treatment","volume":"25","author":"Yegya-Raman","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189008_bb0800","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ijrobp.2020.06.031","article-title":"Novel methodology to investigate the effect of radiation dose to heart substructures on overall survival","volume":"108","author":"McWilliam","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0805","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189008_bb0810","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw.: JNCCN"},{"key":"10.1016\/j.bbcan.2023.189008_bb0815","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40425-016-0166-5","article-title":"Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction","volume":"4","author":"Kanz","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189008_bb0820","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaccao.2020.12.001","article-title":"Management of immune checkpoint inhibitor-induced myocarditis: the French working group\u2019s plea for a pragmatic approach","volume":"3","author":"Thuny","year":"2021","journal-title":"JACC CardioOncol."},{"issue":"42","key":"10.1016\/j.bbcan.2023.189008_bb0825","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.bbcan.2023.189008_bb0830","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0835","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"24","key":"10.1016\/j.bbcan.2023.189008_bb0840","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.bbcan.2023.189008_bb0845","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189008_bb0850","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"issue":"18","key":"10.1016\/j.bbcan.2023.189008_bb0855","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.bbcan.2023.189008_bb0860","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189008_bb0865","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur. J. Heart Fail."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23001579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23001579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T04:32:41Z","timestamp":1719894761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X23001579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":173,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0304419X23001579"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.189008","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.189008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"189008"}}